News articles about Derma Sciences (NASDAQ:DSCI) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Derma Sciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 45.1135038500377 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Derma Sciences (NASDAQ:DSCI) Stock Price” was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.truebluetribune.com/2017/09/17/derma-sciences-dsci-earns-daily-media-impact-rating-of-0-13.html.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.